SHS Gesellschaft für Beteiligungsmanagement has held a first close of its fifth fund at €90 million. SHS V has a target size of €150 million and has raised almost two thirds of this amount in a shorter time than the firm initially anticipated. The fund is dedicated to life sciences and medical technology investments, primarily in Germany and Switzerland, and is expected to make 12 to 15 investments in total.
The investor base for SHS V consists of existing investors and new investors in a 50:50 split.
SHS IV previously closed at €125 million in May 2015 and its investors included Contrium Emission and the EIF.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: